Study highlights significant variation in biomarker testing for non-small-cell lung cancer

Biomarker tests that measure disease-specific molecules are important tools for aiding clinicians in the diagnosis and prognosis of non-small-cell lung cancer (NSCLC). However, the variety of biomarker tests available for NSCLC can make this complicated; therefore, in a recent publication, researchers set out to analyze how these tests are implemented in clinical practice. The study, published in The Journal of Molecular Diagnostics and led by Maarten IJzerman of the University of Twente (Enschede, The Netherlands) and the University of Melbourne (Australia), examined data from a cohort of 102 patients with Stage IV NSCLC who received biomarker tests at a comprehensive...